Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease

Lambert, Jennifer E., Ramos–Roman, Maria A., Browning, Jeffrey D., Parks, Elizabeth J.·2014·Gastroenterology
DOI 10.1053/j.gastro.2013.11.049

Cited by (1,000)

Items 901–1,000 of 1,000

  1. Liver Cancer - Genesis, Progression and Metastasis
    Mark A. Feitelson, Alla L. Arzumanyan · 2022 · IntechOpen eBooks
  2. Glial cell derived neurotrophic factor prevents western diet and palmitate-induced hepatocyte oxidative damage and death through SIRT3
    Simon Musyoka Mwangi, Ge Li, Arun Balasubramaniam, Didier Merlin, Paul A. Dawson, Young Charles Jang, C. Michael Hart, Mark J. Czaja, Shanthi Srinivasan · 2022 · Scientific Reports
  3. Assessment of the relationship between non-alcoholic fatty liver disease and serum zinc levels in obese children and adolescents
    Eren Er · 2023 · Zeynep Kamil Medical Journal
  4. Risk Factors for Non-Alcoholic Fatty Liver Disease in Patients with Bipolar Disorder: A Cross-Sectional Retrospective Study
    Ying Wang, Xuelong Li, Yakun Gao, Xun Zhang, Yiyi Liu, Qing Wu · 2024 · Diabetes Metabolic Syndrome and Obesity
  5. Liver proteomics identifies a disconnect between proteins associated with de novo lipogenesis and triglyceride storage
    Lewin Small, Tuong-Vi Nguyen, Mark Larance, Darren N. Saunders, Andrew J. Hoy, Carsten Schmitz‐Peiffer, Gregory James Cooney, Amanda E. Brandon · 2024 · Journal of Lipid Research
  6. Iridium Isotope Tag-Assisted LC-MS Method for Global Profiling and Quantification of Nonvolatile Serum Fatty Acids in Nonalcoholic Fatty Liver Mice
    Yong-Cheng Dai, Beicheng Zhu, Xueting Yan, Xiaobo Xie, Zixuan Zhan, Yi Lv · 2025 · Analytical Chemistry
  7. Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis
    Barbora Nováková, Ondřej Vrtělka, Kateřina Králová, Lucie Habartová, Vaclav Smid, Karel Dvořák, J Petrtýl, Kateřina Žížalová, Jan Stritesky, Libor Vı́tek et al. · 2025 · Journal of Translational Medicine
  8. Non-coding RNAs Related to Lipid Metabolism and Non-alcoholic Fatty Liver Disease
    Paul Holvoet · 2021 · Springer eBooks
  9. Green Tea and Decaffeinated Light Roasted Green Coffee Extract Combination Improved Cardiac Insulin Resistance through Free Fatty Acids and Adiponectin/FAS Pathway Amelioration in Metabolic Syndrome Rat Model
    Mifetika Lukitasari, Mohammad Saifur Rohman, Dwi Adi Nugroho, Mukhamad Nur Kholis, Nila Aisyah Wahyuni, Nashi Widodo · 2021 · F1000Research
  10. Serum and erythrocyte membrane fatty acid levels may be used as biomarkers to assess the severity of NAFLD
    Маргарита Витальевна Кручинина, М. В. Паруликова, Svetlana A. Kurilovich, Andrei A. Gromov, М. В. Шашков, Anastasiya S. Sokolova, В. Н. Кручинин · 2021 · Экспериментальная и клиническая гастроэнтерология
  11. Isotopic Tracers for the Measurement of Metabolic Flux Rates
    Carine Beysen, Thomas E. Angel, Marc K. Hellerstein, Scott Turner · 2019 · Springer eBooks
  12. Caracterización del papel de la ácido graso translocasa CD36 en la enfermedad hepática grasa no alcohólica y en la hepatitis crónica por virus C
    Miguel Fernández‐Bermejo · 2014 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
  13. Effects of treatment of NAFLD on the metabolic syndrome
    Hannele Yki‐Järvinen · 2016
  14. Hepatic CREBZF as a novel transcriptional regulator of the lipogenic pathway
    Junli Liu · 2019 · Metabolism Open
  15. Pathophysiologic Aspects of Feline Hepatic Lipidosis
    Chiara Valtolina · 2019 · Utrecht University Repository (Utrecht University)
  16. Non‐alcoholic Fatty Liver Disease
    Yaron Rotman, Devika Kapuria · 2020
  17. Long non-coding RNA Gm12664 up-regulates CAV1 expression to promote hepatocellular lipid accumulation by sponging miR-295-5p
    Fei Xu, Liqiang Wang, Linjun Chen, Qingwen Zhang, Lixin Na · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  18. Metabolic Complementation between Glucose and Amino Acid Drives Hepatic De Novo Lipogenesis and Steatosis
    Yilie Liao, Lei Liu, Honghao Li, Xiaojie Bai, Fangfang Sun, Xia Xiao, Suneng Fu · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  19. Associação entre níveis de ácido úrico sérico e o risco para doença gordurosa hepática não alcoólica (DHGNA) nos participantes do Estudo Longitudinal de Saúde do Adulto (EL
    Clara Korukian Freiberg · 2021
  20. Potential uses of water hyacinths in the Tucson area--an addendum for the Pima County Wastewater Management Department
    Peter Warshall, Michael Jennings · 1984
  21. Diabetes and Non‐alcoholic Fatty Liver Disease
    Alessandro Mantovani, Giovanni Targher, Christopher D. Byrne · 2024 · Wiley eBooks
  22. Safety and efficacy of FGF21 analogs in nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials
    Milene Vitória Sampaio Sobral, Hilária Saugo Faria, Lucas Cael Azevedo Ramos Bendaham, Barbara Bombassaro Masiero, Celine Almeida Gouvêa, Giovana de Souza Faria, Marciane Dias dos Santos, Clara de Andrade Pontual Peres, Lídia Ovileira, Eduardo Souto · 2024
  23. Profiling the organ membrane proteome dysregulation in the context of liver disease
    Frank Antony, Zora Brough, Mona Orangi, Hiroyuki Aoki, Mohan Babu, Franck Duong · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  24. Natural Plant Products and their Bioactive Constituents in the Treatment of Obesity
    Nagashree Shamarao, Dugganaboyana Guru Kumar, Mukunda Chethan Kumar · 2024 · Springer eBooks
  25. Non-alcoholic fatty liver disease in patients with diabetes mellitus
    Sohrab Rahimi Naini, Michael A. Fuchs · 2014 · Expert Review of Endocrinology & Metabolism
  26. Role of Lipogenesis and Lipid Desaturases in Non-alcoholic Fatty Liver Disease
    Mohamed Amine Lounis, Sabri Ahmed Rial, James Mukasa Ntambi, Cathérine Mounier · 2015 · Springer eBooks
  27. Participação da conexina 32 na fisiopatogênese da doença hepática gordurosa não alcoólica em camundongos
    Taynã Tiburcio · 2016
  28. Mechanism and functional consequence of MRP2 mislocalization in nonalcoholic steatohepatitis
    Anika L. Dzierlenga · 2016 · UA Campus Repository (The University of Arizona)
  29. Disruption of Hepatocyte Jak2 leads to Spontaneous NASH in Aged Mice and Uncouples Metabolic Liver Disease from Insulin Resistance
    Camella G. Wilson, Aras N. Mattis, Jennifer L. Tran, Kevin C. Corbit, Ethan J. Weiss · 2016 · bioRxiv (Cold Spring Harbor Laboratory)
  30. Regulation of Metabolism by Hepatic OXPHOS: A Dissertation
    Thomas E. Akie · 2015 · The Journal of the American Medical Association (JAMA) Network (American Medical Association)
  31. Proteomics of lipid accumulation and DGAT inhibition in HepG2 liver carcinoma cells
    Bhumika Bhatt-Wessel · 2017
  32. Factors Regulating Features of Metabolic Syndrome
    Sonja S. Pijut · 2017 · UKnowledge (University of Kentucky)
  33. Dietary Manipulation of Gut Microbiota for Improvement of Metabolic Health
    Marc R. Bomhof · 2016 · Libraries and Cultural Resources (University of Calgary)
  34. Effects of LXRα phosphorylation on the regulation of lipid metabolism and hepatic fibrosis
    Natalia Bécares · 2017 · UCL Discovery (University College London)
  35. Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes
    Alfonso Galderisi, Mariangela Martino, Nicola Santoro · 2018 · Elsevier eBooks
  36. The role of folate in non-alcoholic fatty liver disease
    Victoria Sid · 2019 · Mspace (University of Manitoba)
  37. Role of Oxidative Stress in Alcoholic/Non-Alcoholic Liver Diseases
    Keisuke Hino · 2019 · Springer eBooks
  38. A exposição pré-natal à dexametasona exacerba os efeitos da frutose sobre o metabolismo lipídico hepático.
    Tanyara Baliani Payolla · 2019
  39. Obesity-induced hepatic changes during pregnancy
    Luís F. Grilo · 2019 · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
  40. Mechanisms By Which Glucose Lowering Therapies Reduce Obesity And Atherosclerosis
    Emily Anne Day · 2020 · MacSphere (McMaster University)
  41. Metabolic effects of dipeptyl peptidase 4 inhibitor in type 2 diabetes
    Mavin Macauley · 2016
  42. Interplays between nutritional and inflammatory signaling and fat metabolism in pathophysiology of NAFLD
    Juan Zheng, Ting Chen, Xin Guo, James Mukasa Ntambi, Chaodong Wu · 2020 · Elsevier eBooks
  43. Mechanisms of Fibrogenesis in NASH
    Mirella Pastore, Alessandra Gentilini, Fabio Marra · 2020 · Springer eBooks
  44. Nonalcoholic fatty liver disease in relation to cardiovascular disease
    Nynke Simons · 2020
  45. BMI is an Independent Risk Factor for New-onset Asymptomatic Gallbladder Stone Disease in Overweight Population: A Case-control Study in Northwest China
    Binwu Sheng, Jianqin Zhang, Mao Ma, Qingbin Zhao · 2020 · Research Square
  46. Liver substrate metabolism in non-alcoholic fatty liver
    Kay H. M. Roumans · 2021
  47. Lipid metabolism and inflammation in the pathogenesis of chronic liver diseases
    Sowmya Narayanan · 2016
  48. Modelling non-alcoholic fatty liver disease using patient derived liver stem cells and hepatic organoids
    Yee Siang Lim · 2019
  49. What Does Fat Do?
    Nathan Denton · 2021 · Oxford University Press eBooks
  50. Elevated serum S14 levels are associated with more severe liver steatosis by ultrasonography
    Wen-Ti Lin, Kuen‐Cheh Yang, Yen-Ting Chen, Kuo‐Chin Huang, Wei‐Shiung Yang · 2021 · Scientific Reports
  51. Immune dysregulation in nonalcoholic steatohepatitis
    Ankita Chatterjee, Priyadarshi Basu · 2022 · Elsevier eBooks
  52. Exercise and training in NAFLD and insulin resistance
    Bram Brouwers · 2016
  53. Measure for measure?
    Marc K. Hellerstein · 2018 · American Journal of Clinical Nutrition
  54. Magnetic resonance spectroscopy to unravel metabolic alterations in hepatic steatosis in humans
    Pandichelvam Veeraiah · 2021
  55. Proteomics of lipid accumulation and DGAT inhibition in HepG2 liver carcinoma cells
    Bhumika Bhatt-Wessel · 2017
  56. Lipids and nonalcoholic fatty liver disease
    Xiaofei Guo, Wenjun Ma · 2022 · Elsevier eBooks
  57. Progress in research of lipogenesis inhibitors for treatment of nonalcoholic fatty liver disease
    Liu Yang, Jin-Zhong Li, Minran Li · 2022 · World Chinese Journal of Digestology
  58. Modulación de la microbiota intestinal en el tratamiento de la enfermedad de hígado graso no alcohólico y síndrome metabólico. Estudio de un tratamiento experimental con quercetina y de la transferencia de microbiota a ratones libres de gérmenes = Intestinal microbiota modulation in the treatment of non-alcoholic fatty liver disease and metabolic syndrome. Study of an experimental treatment with quercetin and intestinal microbiota transfer to germ-free mice
    David Porras · 2021
  59. Investigação da função hepática de camundongos nocaute para adiponectina induzidos a obesidade por dieta hiperlipídica e suplementados com chá verde.
    Marcelo Paradiso Marinovic · 2021
  60. Association of type 2 diabetes mellitus and other glycemic traits with the risk of NAFLD
    Ziwei Guo, Deming Kong, Hongbo Du, Zhangjun Yun, Jiaxin Zhang, Xiaoke Li, Yongan Ye · 2022 · Research Square
  61. Non-invasive profiling of ectopic and adipose lipids using magnetic resonance spectroscopy and imaging
    Radka Klepochová, Martin Krššák · 2023 · Elsevier eBooks
  62. Lifestyle treatment in the regression of NASH: insulin resistance, lipid synthesis, and methodological innovation
    Justine M. Mucinski · 2022
  63. Non-alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma
    Kai Sun, Alan Wade Hodges, Maen Abdelrahim · 2023 · IntechOpen eBooks
  64. Liver Fat – Gone, but Not Forgotten?
    Paul M. Titchenell, Joseph A. Baur · 2023 · Cellular and Molecular Gastroenterology and Hepatology
  65. Gestational exposure to bisphenol S induces microvesicular steatosis by promoting lipogenesis and inflammation in male rat offspring
    Archana Molangiri, Saikanth Varma, Kota Sri Naga Hridayanka, Myadara Srinivas, Suryam Reddy Kona, Ahamed Ibrahim, Asim K. Duttaroy, Sanjay Basak · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  66. RECENT APPROACHES FOR SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
    Gehan Hussein Heeba, Mohamed Abolnaga, Eman Maher Othman · 2023 · Bulletin of Pharmaceutical Sciences Assiut
  67. Frutose e risco cardiometabólico em indivíduos com preservação da cultura germânica: estudo SHIP-BRASIL
    Tatiana Maria Amaral Zappa · 2022
  68. Non-Alcoholic Fatty Liver Disease (NAFLD): Molecular Mechanism, Pathological Progression and Treatment
    zaher karawia, Mohammed A. Mansour · 2023 · Zagazig Veterinary Journal/Zagazig Veterinary Journal (Online)
  69. Progress on the Role of “Gutbacteria-Gut-Liver Axis” in Non-Alcoholic Fatty Liver Disease
    孟桥 陈 · 2023 · Medical Diagnosis
  70. Editorial: Diabetes and non-alcoholic fatty liver disease: points of physiological and mechanistic intersection and current co-therapeutic approaches
    Nick Giannoukakis, Kyle S. McCommis · 2023 · Frontiers in Endocrinology
  71. Green Tea and Decaffeinated Light Roasted Green Coffee Extract Combination Improved Cardiac Insulin Resistance through Free Fatty Acids and Adiponectin/FAS Pathways Amelioration in Metabolic Syndrome Rat Model
    Mifetika Lukitasari, Mohammad Saifur Rohman, Dwi Adi Nugroho, Mukhamad Nur Kholis, Nila Aisyah Wahyuni, Nashi Widodo · 2023 · F1000Research
  72. Combatting the Fructose Epidemic
    Amée M. Buziau · 2023
  73. A novel Multi Herbal Formulation (AKSS16- LIV01) protects Obesity and associated Nonalcoholic Fatty Liver Disease
    Soumendra Darbar, Srimoyee Saha, Atiskumar Chattopadhyay · 2023 · Current Research in Complementary & Alternative Medicine
  74. The Role of Neutrophil Extracellular Traps (NETs) in Non-alcoholic Fatty Liver Disease (NAFLD): A Comprehensive Analysis of NETs-related Genes
    Zhihao Fang, Xiaoxiao Yu, Changxu Liu, Kai Yang, Yanchao Ji, Chang Liu · 2024 · Research Square
  75. Nonalcoholic fatty liver disease: What comes before and what are the consequences?
    Fernando Bril · 2024 · Elsevier eBooks
  76. 10-Hydroxy-2-Decaenoic Acid Attenuates Nonalcoholic Fatty Liver Disease by Activating Ampk-Α/Acc/Srebp-1/Fasn Signaling Pathway
    Minyi Tang, Xinzi Wang, Shuai Wang, Chaofeng Xing, Qihua Xu, Yunping Mu, Xiaoli Wu, Allan Z. Zhao, Fanghong Li · 2024 · SSRN Electronic Journal
  77. The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
    Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Fernando Bril, Philippe Huot-Marchand, Lucile Lucile, Jens T. Rosenberg, Jean‐Louis Junien, Pierre Broqua, Andrea Ortiz Rocha et al. · 2024 · SSRN Electronic Journal
  78. PROGRESS IN SMALL-MOLECULE DGAT2 INHIBITORS
    Kevin J. Filipski, Kentaro Futatsugi, Robert Dullea, Michelle R. Garnsey, Daniel J. Smaltz · 2024 · Medicinal chemistry reviews
  79. Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
    Fernando Bril, Gabriela Alicia Berg, Magalí Barchuk, Juan Patricio Nogueira · 2025 · Journal of Lipid and Atherosclerosis
  80. Rehabilitation strategies for patients with cholelithiasis after cholecystectomy
    O. Andriichuk, Lidiia Dotsyuk, Юлія Леонідівна Тонкопей · 2025 · Scientific Journal of National Pedagogical Dragomanov University Series 15 Scientific and pedagogical problems of physical culture (physical culture and sports)
  81. Advances in the Pathogenesis of Metabolism-Related Fatty Liver Disease
    红羽 苏 · 2025 · Advances in Clinical Medicine
  82. Hepatic ADMA–PRMT1 axis regulation is associated with NO-dependent endothelial dysfunction in MASH
    Justine Lallement, Sébastian Bott, Hrag Esfahani, Kristian Serafimov, Maxence Henderson, Zoé Benoit, Laurent Dumas, Sultan Al‐Siyabi, Olivier Féron, Isabelle Anne Leclercq et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  83. Potentiality of Stem Cell–Derived Extracellular Vesicles in the Setting of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)
    Angelo Armandi, Gian Paolo Caviglia, Chiara Rosso · 2025 · Stem cells in clinical applications
  84. Safety and Efficacy of FGF21 Analogues in Nonalcoholic Steatohepatitis: A Meta-Analysis of Randomized Clinical Trials
    Milene Vitória Sampaio Sobral, Hilária Saugo Faria, Lucas Cael Azevedo Ramos Bendaham, Barbara Bombassaro Masiero, Celine Almeida Gouvêa, Giovana de Souza Faria, Marciane Dias dos Santos, Clara de Andrade Pontual Peres, Larissa Marrocos de Oliveira, Eduardo Buzatti Souto · 2025 · American Journal of Therapeutics
  85. Lipid-Lowering Activity and Mechanism of Limonoids in Swietenia Macrophylla King by Integrating Network Pharmacology and Rna Sequencing
    Lijuan Sun, Yingwei Liu, Yunpeng Sun, Xiao Huang, Guo‐Kai Wang · 2025 · SSRN Electronic Journal
  86. Estrogen Receptor Beta Activation Coordinates Liver Lipid Remodeling and Metabolic Fluxes, Preventing Lipotoxicity
    Débora Santos Rocha, Eloisa Aparecida Vilas‐Boas, Camille C. Caldeira da Silva, Éverton Lopes Vogt, Marcos Yoshinaga, Mariana Pacheco Teixeira de Carvalho, Maiara I. C. Queiroz, Tiago Eugênio Oliveira da Silva, Sayuri Miyamoto, Alicia Juliana Kowaltowski · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  87. Network pharmacology based investigation of the multi target mechanisms of Murraya koenigii (curry leaves) in non-alcoholic steatohepatitis (NASH)
    Harsh Kashyap, Jyoti Kumari, Manisha Khatri · 2025 · Journal of Complementary and Integrative Medicine
  88. Myths and facts about the role of diet in metabolic dysfunction-associated steatotic liver disease
    Sabrina Alves Fernandes · 2025 · World Journal of Hepatology
  89. Skeletal Muscle and Cardiovascular Health
    Jonathan J. Ruiz‐Ramie, Paul G. Davis, Elizabeth Anderson, John Larry Durstine · 2025 · Advances in experimental medicine and biology
  90. Diabetic Comorbidities and its Molecular Mechanism
    Ahamed Syedh K., A. Pandiselvi, N. Aravindhan, B. Poovarasan, S. Sarankarthikeyan, R. B. Miruthungupta, Harish Kumar E., T. Arulmani · 2025
  91. Endothelial CEPT1 Regulates Hepatic MTTP-Mediated Lipid Metabolism and Impacts Aortic Atherosclerosis
    Dina Ibrahim, Shahab Hafezi, Tariq Khan, Ibrahim Kuziez, Larisa Belaygorod, Chao Yang, Connor Engel, Chenglong Li, Xiaohua Jin, Maxwell Braasch et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  92. HSD17B13 Couples Hepatocyte Lipid Metabolism to Stellate Cell Activation via TGFb-1 Signaling
    Naideline Raymond, Lawrence M. Lifshitz, Kyounghee Min, Caroline A. Lewis, Giorgis Isaac, Batuhan Yenilmez, Michael Czech · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  93. Management and Modification of Flavonoids Against Nonalcoholic Fatty Liver Disease
    Weidong Bai, Bingqi Huang, Wenhong Zhao, Gongliang Liu, Limei Yu, Zhi Lü, Hong Wang · 2025 · Food Bioengineering
  94. Effects of Combined Tunicamycin and a High-Fat Diet Rich in Saturated Fatty Acids on the Development of Steatohepatitis
    Chie Takahashi-Muto, Rieko Tanaka‐Yachi, Chikako Kiyose · 2025 · Journal of Nutritional Science and Vitaminology
  95. Gut microbiota metabolites and insulin resistance parameters as potential indicators of the development and progression of arterial hypertension
    Tatiana Ivanovna Petelina, Ksenia S. Avdeeva, L. L. Valeeva, Aleksandr V. Gorbachevskii, A. A. Kapustina, Liudmila I. Gapon · 2025 · Obesity and metabolism
  96. Global molecular landscape of early MASLD progression in obesity
    Qing Zhao, William De Nardo, Ruoyu Wang, Yi Zhong, Umur Keles, Gabrielé Sakalauskaite, Li Na Zhao, Huiyi Tay, Sonia C. Youhanna, Mengchao Yan et al. · 2025 · eLife
  97. Additional file 5 of Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials
    Peng, Xiaojuan, Juan Li, Hailiang Zhao, Junlong Lai, Junqin Lin, Tang, Shaohui · 2022 · Figshare
  98. Additional file 3 of Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials
    Peng, Xiaojuan, Li, Juan, Hailiang Zhao, Junlong Lai, Junqin Lin, Tang, Shaohui · 2022 · Figshare
  99. Additional file 1 of Fumigaclavine C ameliorates liver steatosis by attenuating hepatic de novo lipogenesis via modulation of the RhoA/ROCK signaling pathway
    W.-L. Yu, Gao, Yaxin, Zaoya Zhao, 龙秀锋, Yi, Yi, Shuo Ai · 2023 · Figshare
  100. Additional file 2 of A novel small compound TOIDC suppresses lipogenesis via SREBP1-dependent signaling to curb MAFLD
    Yaodi Shao, Yao Zhi, Zhou, Junyi, Yu, Miao, Chen, Suzhen, Yuan, Yanmei, Han, Liu, Jiang, Liqin, Liu, Junli · 2024 · Figshare